Skip to main content

Table 2 Changes in ART during follow-up and reasons for each change.

From: Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

ART combination Start Stop Reasons for the changes Lowest number of CD4+ T cells/mmc Highest HIV-RNA load (copies/ml)
Zidovudine, Lamivudine 11/1996 07/1997 Upgrade 147 --
Zidovudine, Lamivudine, Saquinavir 08/1997 02/2000 Poor adherence, virological failure 50 90,387
Stavudine, Lamivudine, Efavirenz 03/2000 04/2000 Skin rash 95 1,164
Stavudine, Lamivudine, Nevirapine 05/2000 08/2000 Patient decision 65 1,245
INTERRUPTION 09/2000 01/2002 -- 9 472,578
Stavudine, Lamivudine 02/2002 04/2002 Upgrade -- --
Stavudine, Lamivudine, Lopinavir/r* 05/2002 04/2003 Patient decision, diarrhea 74 <50
Tenofovir, Lamivudine, Indinavir/r* 05/2003 01/2009 Patient decision 245 <50
Didanosine, Lamivudine, Atazanavir 02/2009 04/2009 Simplification 516 <40
Lamivudine, Atazanavir 05/2009 09/2009 Patient decision 531 119
INTERRUPTION 10/2009 02/2010 -- 291 80,558
Emtricitabine/Tenofovir, Darunavir/r* 02/2010 -- -- 333 734
  1. *r = boosted ritonavir.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us